Freebird Partners LP and related reporting persons amend a Schedule 13G/A to report beneficial ownership of Ernexa Therapeutics Inc. common stock. The filing shows 120,412 shares beneficially owned, representing 9.9% of the class, based on an aggregate outstanding share count of 1,205,328 shares as of May 8, 2026. The reported position combines 81,417 owned shares and shares issuable on exercise of warrants (including 52,000 common warrants and 15,015 pre-funded warrants), with 28,020 warrant shares excluded because of a contractual 9.99% beneficial ownership limitation. The coverages reflect the issuer's 1-for-25 reverse stock split effected May 4, 2026.
Freebird Partners LP and related reporting persons amend a Schedule 13G/A to report beneficial ownership of Ernexa Therapeutics Inc. common stock. The filing shows 120,412 shares beneficially owned, representing 9.9% of the class, based on an aggregate outstanding share count of 1,205,328 shares as of May 8, 2026. The reported position combines 81,417 owned shares and shares issuable on exercise of warrants (including 52,000 common warrants and 15,015 pre-funded warrants), with 28,020 warrant shares excluded because of a contractual 9.99% beneficial ownership limitation. The coverages reflect the issuer's 1-for-25 reverse stock split effected May 4, 2026.
Ernexa Therapeutics Inc. disclosure amends prior Schedule 13G filings to report that John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, share beneficial ownership of 66,751 shares of Common Stock, representing 5.6% of the class.
The filing explains the share count includes (i) 46,445 shares held by the Trust, (ii) 306 shares issuable upon exercise of pre-funded warrants at an exercise price of $1.8750 per share, and (iii) 20,000 shares issuable upon exercise of warrants at $17.00 per share. The percentage is calculated using an aggregate of 1,186,639 shares outstanding (including 20,306 shares issuable within 60 days), and notes the impact of the 1-for-15 and 1-for-25 reverse stock splits.
Ernexa Therapeutics Inc. disclosure amends prior Schedule 13G filings to report that John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, share beneficial ownership of 66,751 shares of Common Stock, representing 5.6% of the class.
The filing explains the share count includes (i) 46,445 shares held by the Trust, (ii) 306 shares issuable upon exercise of pre-funded warrants at an exercise price of $1.8750 per share, and (iii) 20,000 shares issuable upon exercise of warrants at $17.00 per share. The percentage is calculated using an aggregate of 1,186,639 shares outstanding (including 20,306 shares issuable within 60 days), and notes the impact of the 1-for-15 and 1-for-25 reverse stock splits.
Ernexa Therapeutics Inc. reports that Bleichroeder LP and affiliated filers beneficially own 80,000 common shares, equal to 6.86% of the outstanding common stock as of 03/31/2026.
The filing states a 4.99% limitation on warrant exercises; absent that limitation Bleichroeder would be deemed owner of 160,000 shares (about 12.84%). The reporting persons are Bleichroeder Holdings LLC, Bleichroeder LP and Andrew Gundlach.
Ernexa Therapeutics Inc. reports that Bleichroeder LP and affiliated filers beneficially own 80,000 common shares, equal to 6.86% of the outstanding common stock as of 03/31/2026.
The filing states a 4.99% limitation on warrant exercises; absent that limitation Bleichroeder would be deemed owner of 160,000 shares (about 12.84%). The reporting persons are Bleichroeder Holdings LLC, Bleichroeder LP and Andrew Gundlach.
Ernexa Therapeutics Inc. disclosed a Schedule 13G showing Clear Street LLC beneficially owns 149,499 shares of Common Stock, representing 12.8% of the class as of 05/05/2026.
The filing reports sole voting and sole dispositive power over the 149,499 shares. The filing is signed by John DiBacco, Head of Markets Trading for Clear Street LLC.
Ernexa Therapeutics Inc. disclosed a Schedule 13G showing Clear Street LLC beneficially owns 149,499 shares of Common Stock, representing 12.8% of the class as of 05/05/2026.
The filing reports sole voting and sole dispositive power over the 149,499 shares. The filing is signed by John DiBacco, Head of Markets Trading for Clear Street LLC.
Ernexa Therapeutics Inc. amendment updates beneficial ownership for Shameek Konar, Victoria Konar and Regolith Capital Investments LP, reporting 118,342 shares (shared voting and dispositive power) and 48,000 warrants exercisable into common stock. The filing states these amounts reflect a 1-for-15 reverse split (June 10, 2025) and a 1-for-25 reverse split (May 4, 2026).
The filing calculates a 9.7% stake based on 1,214,333 shares outstanding (including 48,000 shares deemed outstanding pursuant to Rule 13-3(d)(1)(i)).
Ernexa Therapeutics Inc. amendment updates beneficial ownership for Shameek Konar, Victoria Konar and Regolith Capital Investments LP, reporting 118,342 shares (shared voting and dispositive power) and 48,000 warrants exercisable into common stock. The filing states these amounts reflect a 1-for-15 reverse split (June 10, 2025) and a 1-for-25 reverse split (May 4, 2026).
The filing calculates a 9.7% stake based on 1,214,333 shares outstanding (including 48,000 shares deemed outstanding pursuant to Rule 13-3(d)(1)(i)).
Ernexa Therapeutics Inc. is asking stockholders to elect five directors, ratify Haskell & White LLP as auditor, and approve a new 2026 Omnibus Equity Incentive Plan at its virtual 2026 annual meeting on July 1, 2026, at 11:00 a.m. Eastern Time.
Holders of Ernexa common stock as of May 6, 2026, when 1,166,333 shares were outstanding, may vote online, by phone, by mail, or electronically during the meeting. The proxy details board structure, committee responsibilities, governance policies, and significant ownership, including a 32.53% stake held by Charles Cherington.
The filing also outlines executive pay, with 2025 total compensation of $888,813 for CEO Sanjeev Luther and $329,372 for Senior Vice President of Finance Sandra Gurrola, plus equity incentive arrangements and severance and change-in-control protections.
Ernexa Therapeutics Inc. is asking stockholders to elect five directors, ratify Haskell & White LLP as auditor, and approve a new 2026 Omnibus Equity Incentive Plan at its virtual 2026 annual meeting on July 1, 2026, at 11:00 a.m. Eastern Time.
Holders of Ernexa common stock as of May 6, 2026, when 1,166,333 shares were outstanding, may vote online, by phone, by mail, or electronically during the meeting. The proxy details board structure, committee responsibilities, governance policies, and significant ownership, including a 32.53% stake held by Charles Cherington.
The filing also outlines executive pay, with 2025 total compensation of $888,813 for CEO Sanjeev Luther and $329,372 for Senior Vice President of Finance Sandra Gurrola, plus equity incentive arrangements and severance and change-in-control protections.
Ernexa Therapeutics, a preclinical synthetic iMSC cell therapy company, reported a first‑quarter 2026 net loss of $5.5 million, smaller than the $8.2 million loss a year earlier. Operating expenses rose to $5.6 million, including $1.9 million in research and development and $1.6 million in general and administrative costs, plus a $2.0 million goodwill impairment.
Ernexa ended March 31, 2026 with $9.2 million in cash, helped by a February public offering that generated approximately $10.5 million in gross proceeds from common stock, pre‑funded warrants and Milestone Warrants. Stockholders also approved a 1‑for‑25 reverse stock split, effective May 4, 2026, leaving 1,166,333 common shares outstanding as of May 8, 2026.
Management notes that April 30, 2026 cash of about $8.3 million is below projected 12‑month needs, but expects access to up to $9.2 million through a newly established at‑the‑market program under a $50 million shelf registration to address forecasted shortfalls, while it advances lead oncology candidate ERNA‑101 toward an IND and Phase 1 trial.
Ernexa Therapeutics, a preclinical synthetic iMSC cell therapy company, reported a first‑quarter 2026 net loss of $5.5 million, smaller than the $8.2 million loss a year earlier. Operating expenses rose to $5.6 million, including $1.9 million in research and development and $1.6 million in general and administrative costs, plus a $2.0 million goodwill impairment.
Ernexa ended March 31, 2026 with $9.2 million in cash, helped by a February public offering that generated approximately $10.5 million in gross proceeds from common stock, pre‑funded warrants and Milestone Warrants. Stockholders also approved a 1‑for‑25 reverse stock split, effective May 4, 2026, leaving 1,166,333 common shares outstanding as of May 8, 2026.
Management notes that April 30, 2026 cash of about $8.3 million is below projected 12‑month needs, but expects access to up to $9.2 million through a newly established at‑the‑market program under a $50 million shelf registration to address forecasted shortfalls, while it advances lead oncology candidate ERNA‑101 toward an IND and Phase 1 trial.
Ernexa Therapeutics Inc. approved a structural change to its capital by filing a Certificate of Amendment in Delaware to implement a 1-for-25 reverse stock split of its common stock. This consolidates every 25 existing shares into 1 share.
The reverse split became effective for trading on Nasdaq at market open on May 4, 2026, when the common stock began trading on a split-adjusted basis under the existing ERNA symbol. The company’s common stock now carries a new CUSIP number, 114082407, following the reverse stock split.
Ernexa Therapeutics Inc. approved a structural change to its capital by filing a Certificate of Amendment in Delaware to implement a 1-for-25 reverse stock split of its common stock. This consolidates every 25 existing shares into 1 share.
The reverse split became effective for trading on Nasdaq at market open on May 4, 2026, when the common stock began trading on a split-adjusted basis under the existing ERNA symbol. The company’s common stock now carries a new CUSIP number, 114082407, following the reverse stock split.
Ernexa Therapeutics Inc. notified shareholders that holders representing approximately 53.34% of voting power approved by written consent a board-authorized reverse stock split to be effected at a ratio between 1-for-10 and 1-for-25, with the Board to select the exact ratio.
The action is intended to regain compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid $1.00). The action will not be effective earlier than 20 days after mailing (on or about April 13, 2026). As of the Record Date there were 29,154,431 shares outstanding and the March 27, 2026 closing price was $0.2020 per share.
Ernexa Therapeutics Inc. notified shareholders that holders representing approximately 53.34% of voting power approved by written consent a board-authorized reverse stock split to be effected at a ratio between 1-for-10 and 1-for-25, with the Board to select the exact ratio.
The action is intended to regain compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid $1.00). The action will not be effective earlier than 20 days after mailing (on or about April 13, 2026). As of the Record Date there were 29,154,431 shares outstanding and the March 27, 2026 closing price was $0.2020 per share.
Ernexa Therapeutics amended its shelf registration to permit up to $50,000,000 of securities and added an ATM sales agreement to sell up to $9,248,276 of common stock under the Sales Agreement with Brookline Capital Markets. The prospectus supplement describes an at-the-market program and notes prior financing: the Company completed a public offering on February 10, 2026 raising net proceeds of approximately $9.5 million and issued warrants, of which 21,000,000 Warrants from that offering remained outstanding as of March 20, 2026. The filing discloses Nasdaq noncompliance: on March 18, 2026 Nasdaq notified the Company that its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days; the Company intends to request a hearing before the Nasdaq Hearing Panel to seek relief after a prior 1-for-15 reverse stock split.
Ernexa Therapeutics amended its shelf registration to permit up to $50,000,000 of securities and added an ATM sales agreement to sell up to $9,248,276 of common stock under the Sales Agreement with Brookline Capital Markets. The prospectus supplement describes an at-the-market program and notes prior financing: the Company completed a public offering on February 10, 2026 raising net proceeds of approximately $9.5 million and issued warrants, of which 21,000,000 Warrants from that offering remained outstanding as of March 20, 2026. The filing discloses Nasdaq noncompliance: on March 18, 2026 Nasdaq notified the Company that its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days; the Company intends to request a hearing before the Nasdaq Hearing Panel to seek relief after a prior 1-for-15 reverse stock split.